IISc Bengaluru TB Breakthrough: Isoniazid + Vancomycin Combo Reverses Drug Resistance in Mycobacterium Tuberculosis
| Detail | Specification |
|---|---|
| Institution | Indian Institute of Science (IISc), Bengaluru |
| Department | Molecular Biophysics Unit / Microbiology |
| Pathogen | Mycobacterium tuberculosis (Mtb) |
| Drug Combo | Isoniazid (INH) + Vancomycin (VAN) |
| Resistance Target | INH-resistant Mtb (katG mutants) |
| Mechanism | Vancomycin permeabilises mycolic acid layer |
| Stage | In vitro validated; murine model next |
| Publication | Nature Microbiology (Nov 2026) |
IISc TB Antibiotic Breakthrough: The Discovery
Researchers at IISc Bengaluru have found that vancomycin — a glycopeptide antibiotic used for Gram-positive bacteria — can reverse isoniazid resistance in Mycobacterium tuberculosis when used in combination. The study, published in Nature Microbiology (November 2026), demonstrates that sub-inhibitory vancomycin disrupts the mycobacterial cell wall, enabling isoniazid to penetrate and kill resistant strains.
The Problem: Isoniazid Resistance
- Isoniazid (INH): First-line TB drug since 1952; pro-drug activated by Mtb catalase-peroxidase KatG
- Resistance mechanism: katG mutations → no INH activation → survival
- Global burden: 4.1 lakh INH-resistant TB cases/year (WHO 2025)
- Current MDR-TB regimen: 6+ drugs, 9–12 months, 50–60% success, severe side effects
How Vancomycin + Isoniazid Works
| Step | Mechanism | Evidence |
|---|---|---|
| 1 | Vancomycin binds D-Ala-D-Ala termini of peptidoglycan precursors | Standard Gram+ mechanism |
| 2 | Inhibits transglycosylation → incomplete mycolic acid-arabinogalactan-peptidoglycan (mAGP) complex | TEM shows cell wall defects |
| 3 | Increased permeability → INH enters cell despite KatG deficiency | Fluorescent INH analog uptake assay |
| 4 | Residual KatG-independent activation → lethal NADH adduct formation | Metabolomics: INH-NAD adduct detected |
| 5 | Synergistic killing: FIC index 0.3 (strong synergy) | Checkerboard assay, 50 clinical isolates |
FIC = Fractional Inhibitory Concentration; ≤0.5 = synergy
Key Results
- MIC reduction: INH MIC drops 32–64× with 0.5× MIC vancomycin
- Strain coverage: 48/50 INH-resistant clinical isolates (including Beijing, CAS, EAI lineages)
- No new resistance: Serial passage (20 generations) — no VAN+INH co-resistance emergence
- Selectivity: No synergy with rifampicin, ethambutol, pyrazinamide — specific to INH
IISc TB Antibiotic Breakthrough: FAQ
- Why vancomycin? It doesn’t work on mycobacteria alone. Vancomycin alone has MIC >256 µg/mL for Mtb (mycolic acid barrier). But at sub-MIC (2–4 µg/mL), it perturbs cell wall assembly enough to let INH in. This is “adjuvant therapy,” not direct killing.
- Is vancomycin safe for TB patients? IV vancomycin is standard for MRSA (dose 15–20 mg/kg q8–12h). Nephro/ototoxicity monitored via trough levels. TB treatment duration (6 mo) similar to endocarditis courses.
- What about oral bioavailability? Vancomycin is IV-only. Oral vancomycin (gut-acting) won’t reach lungs. Inhaled vancomycin (nebulised) under investigation for direct pulmonary delivery — Phase I safety ongoing (IISc + Cipla).
- Does this work for MDR/XDR-TB? Only for INH-mono or INH+RIF resistance where katG is mutated. Not for rpoB (rifampicin) or embB (ethambutol) resistance. But 60% of MDR-TB has INH resistance — major subset.
- Timeline to clinic? 2027: Murine aerosol infection model (IISc + NIRT Chennai) | 2028: Phase I/IIa safety + PK/PD (CTRI registration) | 2030+: WHO guideline inclusion if trials positive.
You May Also Like
- India TB Elimination 2025: Progress, Challenges, New Tools
- IISc Bengaluru Develops Paper-Based TB Diagnostic for Rural India
Sources
- IISc discovers vancomycin restores isoniazid efficacy against drug-resistant TB — Nature Microbiology (Nov 2026) — Primary: mechanism, MIC data, clinical isolates, FIC index, resistance evolution
- IISc press release: New hope for drug-resistant tuberculosis (Nov 2026) — Supporting: researcher quotes, funding (DBT, ICMR, Wellcome Trust), collaboration details
IISc TB Breakthrough in Pictures




